Medytox, a South Korean biopharmaceutical company, announced that its hyaluronic acid (HA) filler, Atiere, has been approved by Thailand's Food and Drug Administration. This approval marks a significant step in Medytox's strategy to expand its global presence in the aesthetics market.
Atiere is formulated with Medytox's proprietary H.E.A.R.T. technology (High, Elastic, Advanced, Rheological, Throughput), designed to optimize elasticity and viscosity. The product uses U.S. FDA-registered hyaluronic acid and is certified by the European Directorate for the Quality of Medicines and Healthcare (EDQM). According to the company, the manufacturing process eliminates animal-derived media and enzymes, reducing the risk of contamination.
The Atiere line includes two formulations tailored to different aesthetic needs:
- Atiere Volume: Designed with large HA particles, this formulation is intended for enhancing areas with significant volume deficiency.
- Atiere Intensive: Featuring medium-sized particles, this formulation is designed for treating moderately deep wrinkles.
This is Atiere's second international approval, following its initial launch in Indonesia in June. Medytox has plans to further expand Atiere’s availability to other countries, complementing its existing HA filler brand, Neuramis, which is already approved in 35 countries, including Thailand.
"The approval of Atiere in Thailand provides strong momentum for Medytox's global filler market strategy," a company official stated. The company intends to promote Atiere locally to create synergy with its botulinum toxin (BTX), Meditoxin, which resumed sales last year after a temporary halt in 2020 due to regulatory issues regarding the use of unapproved raw materials. The Daejeon High Court later ruled the MFDS's actions were excessive and reinstated the product’s license.
